Regulatory14 May 2026, 07:21 pm
Senores Pharma: No Deviation in Preferential Warrant Funds
AI Summary
Senores Pharmaceuticals Ltd. reported no deviations or variations in the utilization of funds raised through the preferential issue of 11,70,000 convertible equity warrants for the quarter ended March 31, 2026. The funds, amounting to ₹95,00,40,000, were raised on March 28, 2026. The Audit Committee reviewed the statement, and the Board of Directors took it on record on May 14, 2026. The original allocation included funding working capital (₹31,25,30,000), product development (₹25,00,00,000), subsidiary investment (₹15,00,00,000), and general corporate purposes (₹23,75,10,000).
Key Highlights
- Senores Pharma reports no deviation in use of funds from preferential warrants.
- ₹95,00,40,000 was raised through preferential issue of warrants.
- Funds utilized for working capital, product development, and subsidiary investment.
- Audit Committee reviewed, and Board took statement on record May 14, 2026.
Price Impact
More from SENORES